Every day, around the globe, Alfaxan injectable anesthetic is used in thousands of anesthesia procedures. Its effectiveness, its wider safety profile and its versatility are raising the bar for injectable agents used in induction and total injectable anesthetic procedures.
And now, Jurox introduces new Alfaxan Multidose, an injectable anesthetic with the same superior pharmacodynamic and pharmacokinetic characteristics as original Alfaxan, but in a preserved formulation that is FDA-approved for 28 days on the shelf, post-broaching.
The Index of legally Marketed Unapproved New Animal Drugs for Minor Species (the Index) is a list of new animal drugs intended for use in minor species that have had their safety and effectiveness affirmed through an alternative FDA process. Jurox Pty Ltd has successfully Indexed Alfaxan® Multidose in cooperation with the Minor Use Minor Species (MUMS) group of the FDA and the product will be legally marketed and sold as Alfaxan® Multidose IDX in the United States. The product has labelling for greater than 50 minor species.